Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways

Keyphrases

• Nanomedicine 100%
• Anti-EGFR 100%
• Insulin-like Growth Factor 1 Receptor (IGF1R) 100%
• Cell Survival Pathways 100%
• Tumor Inhibition 100%
• Nanobullets 100%
• Epidermal Growth Factor Receptor 80%
• IGF1R Signaling 60%
• Tumor 40%
• Liposomes 40%
• Nanobody 40%
• Kinase Inhibitor 40%
• Cytotoxicity 20%
• Insulin-like 20%
• Growth Factors 20%
• Nanocarrier Systems 20%
• Cell Proliferation 20%
• Clinical Efficacy 20%
• Resistance Mechanisms 20%
• Cell Survival 20%
• Combination Therapy 20%
• Healthy Tissue 20%
• Tumor Xenograft Model 20%
• Tumor Cell Proliferation 20%
• Tumor Proliferation 20%
• Molecular Targets 20%
• Receptor Targets 20%
• Proliferation Pathway 20%
• Antitumor Effect 20%
• Survival Pathways 20%
• Tumor Resistance 20%
• Individual Agent 20%
• Antiproliferative Activity 20%
• Unwanted Side Effects 20%
• Degree of Inhibition 20%
• Targeted Inhibitors 20%
• Dual-active 20%
• Cell Proliferation Assay 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Growth 100%
• Epidermal Growth Factor Receptor 100%
• Nanomedicine 83%
• Neoplasm 66%
• Nanobody 33%
• Liposome 33%
• Phosphotransferase Inhibitor 33%
• Nanocarrier 16%
• Molecular Target 16%
• Side Effect 16%
• Somatomedin C 16%
• Tumor Resistance 16%
• Combination Therapy 16%
• Cytotoxicity 16%